Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upneeq in Acquired Blepharoptosis
NCT02436759Phase 3Completed
- Sponsor
- RVL Pharmaceuticals
- Start
- May 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxymetazoline in acquired blepharoptosis, sponsored by RVL Pharmaceuticals. Started May 2015; status: completed.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NCT02436759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436759.